Silencing the roadblocks to effective triple-negative breast cancer treatments by siRNA nanoparticles.
Over the past decade, RNA interference (RNAi) has been ubiquitously utilized to study biological functionin vitro; however, limitations were associated with its utilityin vivoMore recently, small interfering RNA (siRNA) nanoparticles with improved biocompatibility have gained prevalence as a potential therapeutic option for the treatment of various diseases. The adaptability of siRNA nanoparticles enables the delivery of virtually any siRNA, which is especially advantageous for therapeutic applications in heterogeneous diseases that lack unifying molecular features, such as triple-negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer that is stratified by the lack of estrogen receptor/progesterone receptor expression andHER2amplification. There are currently no FDA-approved targeted therapies for the treatment of TNBCs, making cytotoxic chemotherapy the only treatment option available to these patients. In this review, we outline the current status of siRNA nanoparticles in clinical trials for cancer treatment and discuss the promising preclinical approaches that have utilized siRNA nanoparticles for TNBC treatment. Next, we address TNBC subtype-specific therapeutic interventions and highlight where and how siRNA nanoparticles fit into these strategies. Lastly, we point out ongoing challenges in the field of siRNA nanoparticle research that, if addressed, would significantly improve the efficacy of siRNA nanoparticles as a therapeutic option for cancer treatment.
Department of Biomedical EngineeringCase Western Reserve University, Cleveland, Ohio, USA.|Case Comprehensive Cancer CenterCase Western Reserve University, Cleveland, Ohio, USA.
Jenny G
JG
Parvani
Case Comprehensive Cancer CenterCase Western Reserve University, Cleveland, Ohio, USA mwj7@case.edu.
Mark W
MW
Jackson
D000818:Animals; D006801:Humans; D053758:Nanoparticles / Q000627:therapeutic use*; D034741:RNA, Small Interfering / Q000627:therapeutic use*; D064726:Triple Negative Breast Neoplasms / Q000628:therapy*
D034741:RNA, Small Interfering
siRNA nanoparticles; therapeutic strategy; triple-negative breast cancer